08 June 2026
08 June 2026
Findings from the STRIVE study indicated improved glycaemic control with Omnipod 6 compared to Omnipod 5.
The primary endpoint, change in HbA1C after 36 weeks, was met at all doses.
The authorisation covers combination use with miglustat, or as a single therapy if miglustat cannot be tolerated.
The study is structured to assess the anti-tumour efficacy, biomarker effects, recommended dose, safety and tolerability of N17350.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
